Rahul Singhvi, Resilience CEO

Re­silience inks man­u­fac­tur­ing pact with ARCH-backed cell ther­a­py start­up as it preps for the long haul

When you’re aim­ing to be the “Fox­conn” or “Ama­zon Web Ser­vices” of biotech man­u­fac­tur­ing, it’s all about do­ing things dif­fer­ent­ly.

Some of those traits are on dis­play in Re­silience’s lat­est deal, a strate­gic col­lab­o­ra­tion to make Be Bio’s B cell ther­a­pies — or at least the ini­tial rare dis­ease pro­grams.

The pact marks the lat­est deal for a fast mov­ing bio­man­u­fac­tur­ing start­up, which has re­la­tion­ships in place with Take­da, Mod­er­na, blue­bird and Har­vard.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.